These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 28936808)
1. Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis. Harrold LR; John A; Reed GW; Haselkorn T; Karki C; Li Y; Best J; Zlotnick S; Kremer JM; Greenberg JD Rheumatol Ther; 2017 Dec; 4(2):405-417. PubMed ID: 28936808 [TBL] [Abstract][Full Text] [Related]
2. Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis. Harrold LR; Reed GW; Best J; Zlotnick S; Kremer JM Rheumatol Ther; 2018 Dec; 5(2):507-523. PubMed ID: 30293218 [TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048 [TBL] [Abstract][Full Text] [Related]
4. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice. Pappas DA; Etzel CJ; Zlotnick S; Best J; Blachley T; Kremer JM Rheumatol Ther; 2019 Sep; 6(3):421-433. PubMed ID: 31240499 [TBL] [Abstract][Full Text] [Related]
5. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry. Pappas DA; Blachley T; Zlotnick S; Best J; Emeanuru K; Kremer JM Rheumatol Ther; 2020 Jun; 7(2):357-369. PubMed ID: 32232740 [TBL] [Abstract][Full Text] [Related]
6. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA. Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953 [TBL] [Abstract][Full Text] [Related]
7. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. Harrold LR; John A; Best J; Zlotnick S; Karki C; Li Y; Greenberg JD; Kremer JM Clin Rheumatol; 2017 Sep; 36(9):2135-2140. PubMed ID: 28718043 [TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. Lauper K; Mongin D; Iannone F; Kristianslund EK; Kvien TK; Nordström DC; Pavelka K; Pombo-Suarez M; Rotar Z; Santos MJ; Codreanu C; Lukina G; Gale SL; John M; Luder Y; Courvoisier DS; Gabay C Semin Arthritis Rheum; 2020 Feb; 50(1):17-24. PubMed ID: 31280937 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Lauper K; Nordström DC; Pavelka K; Hernández MV; Kvien TK; Kristianslund EK; Santos MJ; Rotar Ž; Iannone F; Codreanu C; Lukina G; Gale SL; Sarsour K; Luder Y; Courvoisier DS; Gabay C Ann Rheum Dis; 2018 Sep; 77(9):1276-1282. PubMed ID: 29730637 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry. Harrold LR; Litman HJ; Connolly SE; Alemao E; Kelly S; Rebello S; Hua W; Kremer JM Rheumatol Ther; 2019 Jun; 6(2):217-230. PubMed ID: 30868550 [TBL] [Abstract][Full Text] [Related]
11. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. Strand V; Michalska M; Birchwood C; Pei J; Tuckwell K; Finch R; Gabay C; Kavanaugh A; Jones G RMD Open; 2017; 3(2):e000496. PubMed ID: 28955499 [TBL] [Abstract][Full Text] [Related]
12. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370 [TBL] [Abstract][Full Text] [Related]
13. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309 [TBL] [Abstract][Full Text] [Related]
14. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL; Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894 [TBL] [Abstract][Full Text] [Related]
15. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153 [TBL] [Abstract][Full Text] [Related]
16. Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry. Pappas DA; Blachley T; Best JH; Zlotnick S; Reiss WG; Emeanuru K; Kremer JM Rheumatol Ther; 2021 Mar; 8(1):467-481. PubMed ID: 33630272 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors. Hattori K; Hirano Y; Kanayama Y; Hattori Y; Kato T; Takahashi N; Ishiguro N; Kojima T Mod Rheumatol; 2021 Jan; 31(1):80-87. PubMed ID: 32148143 [TBL] [Abstract][Full Text] [Related]
19. Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. Strand V; Michalska M; Birchwood C; Pei J; Tuckwell K; Finch R; Kivitz AJ; Smolen JS; Burmester GR RMD Open; 2018; 4(1):e000602. PubMed ID: 29955380 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P; Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]